Japan Approves AstraZeneca, Merek's Lynparza for Advanced Ovarian Cancer
News
Related Biotechnology, Pharmaceutical and Healthcare News
Lynparza is the first poly ADP-ribose
polymerase (PARP) inhibitor to be approved in Japan.
Original Article: Japan Approves AstraZeneca, Merek's Lynparza for Advanced Ovarian Cancer
NEXT ARTICLE
More From BioPortfolio on "Japan Approves AstraZeneca, Merek's Lynparza for Advanced Ovarian Cancer"